基于基因型耐药检测指导的格拉瑞韦-艾尔巴韦联合或不联合利巴韦林在人类免疫缺陷病毒/丙型肝炎病毒共感染男男性行为者中治愈率高
在瑞士HCVree试验中,对3722名MSM进行HCV RNA筛查,177人(4.8%)存在复制性感染,122人(3.3%)符合格拉瑞韦-艾尔巴韦治疗条件。基因1a型伴基线耐药相关替换者及基因4型既往治疗失败者接受16周格拉瑞韦-艾尔巴韦联合利巴韦林,其余接受12周单药治疗。停药12周后持续病毒学应答率达99%(121/122),8例严重不良事件均与研究药物无关。
要点
- 基因1a型伴基线RAS者及基因4型既往治疗失败者接受16周格拉瑞韦-艾尔巴韦联合利巴韦林。
- 其余患者接受12周格拉瑞韦-艾尔巴韦单药治疗,总体SVR12达99%(121/122)。
- 8例严重不良事件均与研究药物无关,75%符合条件MSM参与了风险降低行为干预。
核心结论
- 格拉瑞韦-艾尔巴韦治疗12或16周,联合或不联合利巴韦林,在HIV/HCV共感染MSM中治愈率高且安全性极好。
- 治疗时长由基因1a型感染者的基线RAS决定,治疗期间伴随HCV风险降低行为干预,此策略为实现MSM共感染人群HCV消除奠定基础。
研究设计与样本
- 瑞士HCVree试验,对瑞士HIV队列研究中所有MSM进行HCV RNA筛查,复制性HCV基因1或4型感染者符合格拉瑞韦-艾尔巴韦治疗条件。
- 基因1a型伴基线RAS者及基因4型既往HCV治疗失败者接受16周格拉瑞韦-艾尔巴韦联合利巴韦林,其余接受12周格拉瑞韦-艾尔巴韦单药治疗。
- 报告与偶遇性伴发生无保护性行为的患者接受HCV风险降低行为干预。
主要发现
- 筛查3722名MSM,177人(4.8%)存在复制性感染,122人(3.3%)符合研究治疗条件。
- 76例基因1a型感染者中6例(7.3%)携带基线RAS。
- 停药12周后持续病毒学应答在121例患者中达成(99%),包括所有基因1a型感染者。
- 共发生8例严重不良事件,均与研究药物无关。
- 75%符合条件MSM参与了风险咨询项目。
关键数值与推荐
- 基因1a型伴基线RAS者及基因4型既往治疗失败者:格拉瑞韦-艾尔巴韦联合利巴韦林治疗16周。
- 其他符合条件者:格拉瑞韦-艾尔巴韦单药治疗12周。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was performed to investigate the efficacy and safety of grazoprevir-elbasvir guided by baseline resistance-associated substitutions (RASs) in the Swiss HCVree Trial. METHODS: We performed hepatitis C virus (HCV) RNA screening among all men who have sex with men (MSM) enrolled in the Swiss HIV Cohort Study. Individuals with replicating HCV genotype 1 or 4 infection were eligible for grazoprevir-elbasvir treatment. Genotype 1a-infected individuals with baseline RASs and genotype 4-infected individuals with prior failure of HCV treatment received 16 weeks of grazoprevir-elbasvir combined with ribavirin. All other individuals received 12 weeks of grazoprevir-elbasvir alone. Patients reporting unprotected sex with occasional partners were offered a HCV risk reduction-oriented behavioral intervention. RESULTS: We screened 3722 MSM and identified 177 (4.8%) with replicating infection. A total of 122 individuals (3.3%) were eligible for study treatment. Six of 76 patients infected with genotype 1a (7.3%) harbored baseline RASs. Sustained virological response after 12 weeks of follow-up was achieved in 121 patients (99%), including all with genotype 1a infection. Overall, 8 serious adverse events occurred, none of which was related to the study drug. Seventy-five percent of eligible MSM participated in the risk counseling program. CONCLUSIONS: Grazoprevir-elbasvir for 12 or 16 weeks, with or without ribavirin, achieved high cure rates and had an excellent safety profile. Unique to other studies, the treatment duration was guided by the presence of baseline RASs among genotype 1a-infected individuals, and the treatment phase was accompanied by an HCV risk reduction-oriented behavioral intervention. This successful population-wide treatment approach lays the groundwork to achieve HCV elimination in coinfected MSM. CLINICAL TRIALS REGISTRATION: NCT02785666.
引用
- Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis. 2019. PMID: 30107485. doi:10.1093/cid/ciy547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。